Asia Pacific Polio Vaccine Market Insights Forecasts to 2033

• The Asia Pacific Polio Vaccine Market Size was valued at USD 384.17 Million in 2023.
• The Market is Growing at a CAGR of 4.07% from 2023 to 2033
• The Asia Pacific Polio Vaccine Market Size is Expected to Reach USD 572.25 Million by 2033

The Asia Pacific Polio Vaccine Market is Anticipated to Reach USD 572.25 Million by 2033, growing at a CAGR of 4.07% from 2023 to 2033.

Market Overview

The primary medical advancement created to prevent poliomyelitis, also known as polio, is the polio vaccination. The poliovirus is the primary cause of this extremely contagious viral disease that predominantly affects the neurological system and can cause paralysis, weakening of the muscles, and even death. The rising number of births and the growing population are two factors driving the increasing need for the polio vaccination. The polio vaccination was affordable and available to everyone due to its low cost. The comprehensive strategy contributes to raising public knowledge of the value of immunization in preventing disease, which increases demand for polio vaccinations. One of the main factors driving the growth of the polio vaccine market in the Asia Pacific is the ongoing introduction of new technologies that improve the functionality and efficiency of products.    

Report Coverage

This research report categorizes the market for the Asia Pacific polio vaccine market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Asia Pacific polio vaccine market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Asia Pacific polio vaccine market.

Driving Factors

The polio vaccine market is driving primarily due to the rising costs associated with the vaccine's scientific research. A great deal of research is being done to develop several polio vaccines. This is driving an increase in the annual doses of the polio vaccination. The polio vaccine market is predicted to increase due to the government's increased awareness of the need to vaccinate against viruses. The market for polio vaccinations is expanding significantly as a result of a mix of growing consumer demand, industry investments, and technological developments.

Restraining Factors

Impaired infrastructure and a challenging environment can hinder immunization efforts. Parents can be discouraged from vaccinating their children due to disinformation and misconceptions regarding vaccines. These are some of the variables restricting the growth of the Asia Pacific polio vaccine market.

Market Segmentation

The Asia Pacific polio vaccine market share is classified into type and application.

• The oral polio vaccine (OPV) segment is expected to hold the largest market share through the forecast period.

The Asia Pacific polio vaccine market is segmented by type into inactivated polio vaccine (IPV) and oral polio vaccine (OPV). Among these, the oral polio vaccine (OPV) segment is expected to hold the largest market share through the forecast period. The strains used in the oral polio vaccination help in the production of antibodies to fight against the wild or naturally occurring poliovirus in youngsters. Positive aspects include the simplicity of access and consumption contributing to the oral polio vaccine market growth.    

• The public segment is expected to dominate the Asia Pacific polio vaccine market during the forecast period.       

Based on the application, the Asia Pacific polio vaccine market is divided into public and private. Among these, the public segment is expected to dominate the Asia Pacific polio vaccine market during the forecast period. The Asia-Pacific region's governments and public organizations have been heavily involved in polio vaccine initiatives to end the disease. To promptly identify and contain any outbreaks, governments, and health organizations also prioritize surveillance and case monitoring for possible polio cases.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Asia Pacific polio vaccine market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Biological E
• GSK
• Serum Institute
• Bharat Biotech
• Novartis International AG
• Sinovac Biotech
• Panacea Biotec Ltd
• Merck & Co., Inc.
• Bio-Med (P) Limited
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In July 2024, to help prevent circulating vaccine-derived poliovirus type 2 (cVDPV2) outbreaks, Biological E, an Indian pharmaceutical and vaccine business, recently announced that the World Health Organization had prequalified its innovative oral poliovirus type 2 (nOPV2) vaccine.   

Market Segment

This study forecasts revenue at Asia Pacific, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the Asia Pacific polio vaccine market based on the below-mentioned segments:

Asia Pacific Polio Vaccine Market, By Type

• Inactivated polio vaccine (IPV)
• Oral polio vaccine (OPV)

Asia Pacific Polio Vaccine Market, By Application

• Public
• Private